Morgan Stanley Issues Positive Forecast for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price

by · The Markets Daily

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its price objective upped by research analysts at Morgan Stanley from $767.00 to $768.00 in a report issued on Friday,Benzinga reports. The brokerage presently has an “equal weight” rating on the biopharmaceutical company’s stock. Morgan Stanley’s price target indicates a potential upside of 4.12% from the company’s previous close.

A number of other analysts have also recently commented on REGN. Bank of America upped their price objective on Regeneron Pharmaceuticals from $543.00 to $627.00 and gave the company an “underperform” rating in a research report on Wednesday, October 29th. Wells Fargo & Company lifted their target price on Regeneron Pharmaceuticals from $700.00 to $745.00 and gave the stock an “equal weight” rating in a report on Wednesday. Hsbc Global Res raised Regeneron Pharmaceuticals to a “strong-buy” rating in a research note on Monday, November 24th. Rothschild & Co Redburn assumed coverage on Regeneron Pharmaceuticals in a research note on Thursday, August 14th. They issued a “buy” rating and a $890.00 price objective on the stock. Finally, Sanford C. Bernstein upped their price objective on Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the stock an “outperform” rating in a report on Wednesday, August 27th. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $779.45.

Check Out Our Latest Research Report on REGN

Regeneron Pharmaceuticals Trading Down 1.2%

Shares of NASDAQ:REGN traded down $9.22 during midday trading on Friday, hitting $737.58. 233,919 shares of the stock traded hands, compared to its average volume of 1,096,572. The business’s 50 day moving average is $661.61 and its two-hundred day moving average is $591.76. The stock has a market capitalization of $77.52 billion, a PE ratio of 17.66, a P/E/G ratio of 2.08 and a beta of 0.37. The company has a quick ratio of 3.33, a current ratio of 4.06 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals has a one year low of $476.49 and a one year high of $790.98.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last issued its quarterly earnings data on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share for the quarter, topping analysts’ consensus estimates of $9.73 by $2.10. The firm had revenue of $3.75 billion for the quarter, compared to analyst estimates of $3.57 billion. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The business’s quarterly revenue was up .9% compared to the same quarter last year. During the same period last year, the company earned $12.46 EPS. As a group, research analysts forecast that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current year.

Insider Activity

In other Regeneron Pharmaceuticals news, Director Christine A. Poon sold 6,500 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, October 29th. The shares were sold at an average price of $654.27, for a total transaction of $4,252,755.00. Following the completion of the sale, the director directly owned 2,352 shares in the company, valued at approximately $1,538,843.04. The trade was a 73.43% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, VP Jason Pitofsky sold 431 shares of the business’s stock in a transaction on Friday, November 7th. The shares were sold at an average price of $651.43, for a total transaction of $280,766.33. Following the transaction, the vice president owned 4,233 shares of the company’s stock, valued at $2,757,503.19. This represents a 9.24% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Company insiders own 7.02% of the company’s stock.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

A number of large investors have recently bought and sold shares of the business. PGGM Investments raised its stake in shares of Regeneron Pharmaceuticals by 159.7% in the second quarter. PGGM Investments now owns 84,397 shares of the biopharmaceutical company’s stock valued at $44,308,000 after acquiring an additional 51,900 shares in the last quarter. Founders Capital Management LLC raised its stake in shares of Regeneron Pharmaceuticals by 7.0% during the second quarter. Founders Capital Management LLC now owns 8,274 shares of the biopharmaceutical company’s stock worth $4,344,000 after purchasing an additional 538 shares during the last quarter. Sepio Capital LP lifted its holdings in shares of Regeneron Pharmaceuticals by 33.1% during the first quarter. Sepio Capital LP now owns 3,389 shares of the biopharmaceutical company’s stock worth $2,150,000 after purchasing an additional 842 shares during the period. Generate Investment Management Ltd purchased a new position in Regeneron Pharmaceuticals in the 2nd quarter valued at $6,300,000. Finally, Bellecapital International Ltd. increased its stake in Regeneron Pharmaceuticals by 32.7% in the 2nd quarter. Bellecapital International Ltd. now owns 25,503 shares of the biopharmaceutical company’s stock valued at $13,389,000 after buying an additional 6,283 shares during the period. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

(Get Free Report)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Featured Stories